Feb 17, 2021
Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Nov 23, 2020
Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 06, 2020
Ardelyx to Webcast Virtual Analyst Day
Oct 22, 2020
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
Oct 12, 2020
Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
Sep 15, 2020
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Aug 06, 2020
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
Aug 03, 2020
Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
Jun 30, 2020
Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
Jun 15, 2020
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
Jun 09, 2020
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 08, 2020
Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
May 26, 2020
Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
May 21, 2020
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2020
Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
Mar 06, 2020
Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
Feb 26, 2020
Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference
Dec 04, 2019
Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
Dec 04, 2019
Ardelyx Announces Proposed Public Offering of Common Stock
Dec 03, 2019
Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis